ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022
Pseudomonas aeruginosa Biofilm Dispersion by the Human Atrial Natriuretic Peptide.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Bioinspired Antimicrobial Strategy: An Extremophile Deep Sea Peptide to Combat Cystic Fibrosis Infections Caused byMarine drugs · 2026Article
- Stigmurin derivatives as potent-biofilm eradicating agents against the major human opportunistic pathogenFrontiers in microbiology · 2026Article
- RNA-binding antiterminators: regulation of metabolism and pathogenicity in bacteria.RNA biology · 2025Review
- Quinazoline-Derivatives of Imino-1,2,3-Dithiazoles Promote Biofilm Dispersion ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Squalamine and claramine A1 disperseBiofilm · 2025Article
- Antibiofilm Activities of Tritrpticin Analogs Against PathogenicMolecules (Basel, Switzerland) · 2025Article
- Intracellular Pseudomonas aeruginosa persist and evade antibiotic treatment in a wound infection model.PLoS pathogens · 2025Article
- Therapeutic Interventions forJournal of clinical medicine · 2024Review
- Pseudomonas aeruginosa senses and responds to epithelial potassium flux via Kdp operon to promote biofilm.PLoS pathogens · 2024Article
- Carboxymethyl chitosan nanoparticle-modulated cationic hydrogels doped with copper ions for combating bacteria and facilitating wound healing.Frontiers in bioengineering and biotechnology · 2024Article
- Biofilm formation: mechanistic insights and therapeutic targets.Molecular biomedicine · 2023Review
- A-Type Natriuretic Peptide Alters the Impact of Azithromycin on Planktonic Culture and on (Monospecies and Binary) Biofilms of Skin BacteriaMicroorganisms · 2023Article
- Epinephrine Affects Ribosomes, Cell Division, and Catabolic Processes inMicroorganisms · 2023Article
- Combating Bacterial Biofilms: Current and Emerging Antibiofilm Strategies for Treating Persistent Infections.Antibiotics (Basel, Switzerland) · 2023Review
- C-Type Natriuretic Peptide Acts as a Microorganism-Activated Regulator of the Skin CommensalsBiology · 2023Article
- Perspective: The viscoelastic properties of biofilm infections and mechanical interactions with phagocytic immune cells.Frontiers in cellular and infection microbiology · 2023Review
- A global bibliometric and visualized analysis of bacterial biofilm eradication from 2012 to 2022.Frontiers in microbiology · 2023Review
- Innovative Strategies to Overcome Antimicrobial Resistance and Tolerance.Microorganisms · 2022Review
- Targeted Anti-Biofilm Therapy: Dissecting Targets in the Biofilm Life Cycle.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Pseudomonas aeruginosa biofilm dispersion by the mouse antimicrobial peptide CRAMP.Veterinary research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 2 countries.
Funding
Abstract
Pseudomonas aeruginosa biofilms cause chronic, antibiotic tolerant infections in wounds and lungs. Numerous recent studies demonstrate that bacteria can detect human communication compounds through specific sensor/receptor tools that modulate bacterial physiology. Consequently, interfering with these mechanisms offers an exciting opportunity to directly affect the infection process. It is shown that the human hormone Atrial Natriuretic Peptide (hANP) both prevents the formation of P. aeruginosa biofilms and strongly disperses established P. aeruginosa biofilms. This hANP action is dose-dependent with a strong effect at low nanomolar concentrations and takes effect in 30-120 min. Furthermore, although hANP has no antimicrobial effect, it acts as an antibiotic adjuvant. hANP enhances the antibiofilm action of antibiotics with diverse modes of action, allowing almost full biofilm eradication. The hANP effect requires the presence of the P. aeruginosa sensor AmiC and the AmiR antiterminator regulator, indicating a specific mode of action. These data establish the activation of the ami pathway as a potential mechanism for P. aeruginosa biofilm dispersion. hANP appears to be devoid of toxicity, does not enhance bacterial pathogenicity, and acts synergistically with antibiotics. These data show that hANP is a promising powerful antibiofilm weapon against established P. aeruginosa biofilms in chronic infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.